DIN 02561026 — OMLYCLO 150 MG
OMLYCLO is a solution of Omalizumab marketed by CELLTRION INC.. The full Omalizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02561026
- Brand name
- OMLYCLO
- Active ingredient
- Omalizumab
- Strength
- 150 MG
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- CELLTRION INC.
- Health Canada status
- MARKETED
- Drug class
- IgE-neutralizing antibody (anti-IgE monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Omalizumab products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02553813 | OMLYCLO | 150 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02553805 | OMLYCLO | 75 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02561018 | OMLYCLO | 75 MG | SOLUTION | CELLTRION INC. | MARKETED |
| 02260565 | XOLAIR | 150 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02459795 | XOLAIR | 150 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02545144 | XOLAIR | 150 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02545160 | XOLAIR | 300 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02459787 | XOLAIR | 75 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02545136 | XOLAIR | 75 MG | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |